ORIC Pharmaceuticals

company

About

ORIC Pharmaceuticals operates as a biopharmaceutical company.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$25M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:ORIC
Legal Name
ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$318M
ORIC Pharmaceuticals has raised a total of $318M in funding over 2 rounds. Their latest funding was raised on Dec 21, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 21, 2022 Post-IPO Equity $25M 1 Pfizer Detail
Apr 24, 2020 IPO $120M Detail
Aug 9, 2019 Series D $55M 16 ArrowMark Partners
Invus
Detail
Feb 21, 2018 Series C $50M 11 Fidelity Management and Research Company Detail
Dec 2, 2015 Series B $53M 6 The Column Group Detail

Investors

Number of Lead Investors
Number of Investors
6
21
ORIC Pharmaceuticals is funded by 21 investors. Pfizer and ArrowMark Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Pfizer Yes Post-IPO Equity
ArrowMark Partners Yes Series D
Invus Yes Series D
Casdin Capital Series D
City Hill Ventures Series D
Correlation Ventures Series D
EcoR1 Capital Series D
Fidelity Management and Research Company Series D
Foresite Capital Series D
Hartford HealthCare Endowment Series D

Employee Profiles

Number of Employee Profiles
15
ORIC Pharmaceuticals has 15 current employee profiles, including Board member Carl L. Gordon
Board member
Board member
Board member
Executive
Board member